tiprankstipranks
Agilon Health (AGL)
NYSE:AGL
US Market
Want to see AGL full AI Analyst Report?

Agilon Health (AGL) Stock Forecast & Price Target

394 Followers
See the Price Targets and Ratings of:

AGL Analyst Ratings

Hold
12Ratings
Hold
2 Buy
9 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Agilon
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGL Stock 12 Month Forecast

Average Price Target

$113.22
▲(17.80% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Agilon Health in the last 3 months. The average price target is $113.22 with a high forecast of $146.00 and a low forecast of $85.00. The average price target represents a 17.80% change from the last price of $96.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","147":"$147","42.75":"$42.8","77.5":"$77.5","112.25":"$112.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$146.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.22222222222223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,42.75,77.5,112.25,147],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.47,91.9723076923077,96.47461538461539,100.97692307692307,105.47923076923077,109.98153846153846,114.48384615384614,118.98615384615384,123.48846153846154,127.99076923076923,132.49307692307693,136.9953846153846,141.49769230769232,{"y":146,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.47,89.45094017094017,91.43188034188034,93.41282051282052,95.39376068376069,97.37470085470086,99.35564102564103,101.3365811965812,103.31752136752137,105.29846153846154,107.27940170940171,109.26034188034188,111.24128205128206,{"y":113.22222222222223,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.47,87.28,87.09,86.9,86.71,86.52,86.33,86.14,85.95,85.76,85.57,85.38,85.19,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.912,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.549,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.217,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.697,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.387,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.61,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":87.47,"date":1788220800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$146.00Average Price Target$113.22Lowest Price Target$85.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$86
Hold
-10.52%
Downside
Reiterated
09/09/26
Bernstein Reaffirms Their Hold Rating on Agilon Health (AGL)
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
$31$85
Sell
-11.56%
Downside
Reiterated
08/24/26
J.P. Morgan Reaffirms Their Sell Rating on Agilon Health (AGL)
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (NASDAQ: ELOX), Cingulate Inc (NASDAQ: CING) and Agilon Health (NYSE: AGL)
Citi
$105$115
Hold
19.65%
Upside
Upgraded
08/11/26
Agilon Health upgraded to Neutral from Sell at CitiAgilon Health upgraded to Neutral from Sell at Citi
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$141$146
Buy
51.91%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)
TD Cowen
$55$95
Hold
-1.15%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Globus Medical (NYSE: GMED)
Evercore ISI
$120$125
Hold
30.06%
Upside
Reiterated
08/06/26
Agilon Health price target raised to $125 from $120 at Evercore ISIAgilon Health price target raised to $125 from $120 at Evercore ISI
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$95$140
Buy
45.67%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Qiagen (NYSE: QGEN) and Coherus Biosciences (NASDAQ: CHRS)
Needham
Hold
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$35$116
Hold
20.70%
Upside
Reiterated
08/06/26
Agilon Health price target raised to $116 from $35 at BairdAgilon Health price target raised to $116 from $35 at Baird
Barclays
$81$111
Hold
15.49%
Upside
Reiterated
08/06/26
Agilon Health (AGL) Receives a Hold from Barclays
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
08/05/26
Hold Rating Maintained on agilon health as Turnaround Progress and Improved Guidance Appear Priced In
Deutsche Bank  Analyst forecast on AGL
Deutsche Bank
Deutsche Bank
$33$49
Buy
-49.02%
Downside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at Deutsche BankAgilon Health upgraded to Buy from Hold at Deutsche Bank
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$27.5$48
Buy
-50.06%
Downside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at JefferiesAgilon Health upgraded to Buy from Hold at Jefferies
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
$6.25$22
Sell
-77.11%
Downside
Reiterated
05/07/26
Agilon Health (AGL) Receives a Sell from Bank of America Securities
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$86
Hold
-10.52%
Downside
Reiterated
09/09/26
Bernstein Reaffirms Their Hold Rating on Agilon Health (AGL)
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
$31$85
Sell
-11.56%
Downside
Reiterated
08/24/26
J.P. Morgan Reaffirms Their Sell Rating on Agilon Health (AGL)
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (NASDAQ: ELOX), Cingulate Inc (NASDAQ: CING) and Agilon Health (NYSE: AGL)
Citi
$105$115
Hold
19.65%
Upside
Upgraded
08/11/26
Agilon Health upgraded to Neutral from Sell at CitiAgilon Health upgraded to Neutral from Sell at Citi
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$141$146
Buy
51.91%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)
TD Cowen
$55$95
Hold
-1.15%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Globus Medical (NYSE: GMED)
Evercore ISI
$120$125
Hold
30.06%
Upside
Reiterated
08/06/26
Agilon Health price target raised to $125 from $120 at Evercore ISIAgilon Health price target raised to $125 from $120 at Evercore ISI
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$95$140
Buy
45.67%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Qiagen (NYSE: QGEN) and Coherus Biosciences (NASDAQ: CHRS)
Needham
Hold
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$35$116
Hold
20.70%
Upside
Reiterated
08/06/26
Agilon Health price target raised to $116 from $35 at BairdAgilon Health price target raised to $116 from $35 at Baird
Barclays
$81$111
Hold
15.49%
Upside
Reiterated
08/06/26
Agilon Health (AGL) Receives a Hold from Barclays
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
08/05/26
Hold Rating Maintained on agilon health as Turnaround Progress and Improved Guidance Appear Priced In
Deutsche Bank  Analyst forecast on AGL
Deutsche Bank
Deutsche Bank
$33$49
Buy
-49.02%
Downside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at Deutsche BankAgilon Health upgraded to Buy from Hold at Deutsche Bank
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$27.5$48
Buy
-50.06%
Downside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at JefferiesAgilon Health upgraded to Buy from Hold at Jefferies
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
$6.25$22
Sell
-77.11%
Downside
Reiterated
05/07/26
Agilon Health (AGL) Receives a Sell from Bank of America Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
STOKStoke Therapeutics
AXGNAxoGen
JAZZJazz Pharmaceuticals
PTGXProtagonist Therapeutics
CABACabaletta Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilon Health

3 Months
George HillDeutsche Bank
Success Rate
5/11 ratings generated profit
45%
Average Return
+1.54%
Copying George Hill's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +1.54% per trade.
1 Year
Bill SutherlandBenchmark Co.
Success Rate
6/13 ratings generated profit
46%
Average Return
+87.83%
Copying Bill Sutherland's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +87.83% per trade.
2 Years
Bill SutherlandBenchmark Co.
Success Rate
7/13 ratings generated profit
54%
Average Return
+92.35%
Copying Bill Sutherland's trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +92.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGL Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
2
2
Buy
5
5
5
1
1
Hold
19
17
14
15
16
Sell
2
1
2
3
3
Strong Sell
2
2
2
0
0
total
28
25
23
21
22
In the current month, AGL has received 3 Buy Ratings, 16 Hold Ratings, and 3 Sell Ratings. AGL average Analyst price target in the past 3 months is 113.22.
Each month's total comprises the sum of three months' worth of ratings.

AGL Financial Forecast

AGL Earnings Forecast

Next quarter’s earnings estimate for AGL is -$1.18 with a range of -$3.44 to -$0.25. The previous quarter’s EPS was $1.04. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s earnings estimate for AGL is -$1.18 with a range of -$3.44 to -$0.25. The previous quarter’s EPS was $1.04. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Sales Forecast

Next quarter’s sales forecast for AGL is $1.46B with a range of $1.41B to $1.47B. The previous quarter’s sales results were $1.49B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s sales forecast for AGL is $1.46B with a range of $1.41B to $1.47B. The previous quarter’s sales results were $1.49B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Stock Forecast FAQ

What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health’s 12-month average price target is 113.22.
    What is AGL’s upside potential, based on the analysts’ average price target?
    Agilon Health has 17.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGL a Buy, Sell or Hold?
          Agilon Health has a consensus rating of Hold which is based on 2 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Agilon Health’s price target?
            The average price target for Agilon Health is 113.22. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $146.00 ,the lowest forecast is $85.00. The average price target represents 17.80% Increase from the current price of $96.11.
              What do analysts say about Agilon Health?
              Agilon Health’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of AGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.